Articles Vol. 67 No. Số CĐ12- Bệnh viện Ung bướu Nghệ An (2026) 14/08/2026

THE EFFICACY OF ENDOCRINE COMBINED WITH CDK4/6 INHIBITORS IN PATIENTS WITH HORMONE RECEPTOR - POSITIVE, HER2 - NEGATIVE RECURRENT OR METASTATIC BREAST CANCER

Pham Thi Hoang Phuong1,2, Tran Thi Dung1,2, Phan Thi Nhu Quynh1,2
1 Nghe An Oncology Hospital
2 Bệnh viện Ung Bướu Nghệ An
DOI: 10.52163/yhc.v67iCD12.6144
629 Views
0 Downloads
Keywords
Recurrent or metastatic breast cancer, hormone receptor-positive, HER2-negative, CDK4/6 inhibitors.
Abstract
  1. Objectives: To describe the clinical and

 paraclinical characteristics and evaluate the efficacy of endocrine therapy combined with CDK4/6 inhibitors in patients with hormone receptor-positive, HER2-negative (HR+/HER2-) recurrent or metastatic breast cancer.

  1. Methods: A combined retrospective and prospective descriptive study (involving clinical and imaging follow-up) was conducted on 32 patients diagnosed with HR+/HER2- recurrent or metastatic breast carcinoma. Data collection took place at the Department of Internal Medicine IV, Nghe An Oncology Hospital, from April 2023 to June 2026. The data cut-off date for analysis was June 10, 2026. The median follow-up duration was 9.7 months (with a minimum follow-up of 3.1 months).
  2. Results: The mean age at the time of recurrence or metastasis was 58.09 years. The majority of patients had a good performance status (ECOG 0) at 78.1%; invasive ductal carcinoma accounted for 81.3%, and 81.3% had histological grade 2. The rate of late recurrence (more than 1 year after radical treatment) reached 65.6%. The most common metastatic or invasive sites included bone (56.3%), lung (56.3%), and peripheral lymph nodes (43.8%). The overall response rate (ORR) of the regimen was 37.5%; in which complete response was 3.1%, partial response was 34.4%, and stable disease was 37.5%, resulting in a clinical benefit rate (CBR) of 75.0%. The median progression-free survival (PFS) extended to 32.1 months.
  3. Conclusion: The combination regimen of endocrine therapy and CDK4/6 inhibitors in patients with HR+/HER2- recurrent or metastatic breast cancer demonstrated favorable results regarding response rates and progression-free survival. This regimen proved feasible, was well-tolerated, and provided positive clinical benefits in a real-world clinical setting.
References
[1]
Bệnh viện K. Báo Cáo Ghi Nhận Ung Thư Việt Nam 2022. 2023. Google Scholar
[2]
Hortobagyi GN, Stemmer SM, Burris HA, et al. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29(7). doi:10.1093/annonc/mdy155 Google Scholar
[3]
Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925-1936. doi:10.1056/NEJMoa1607303 Google Scholar
[4]
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 4.2024). National Comprehensive Cancer Network; 2024. Google Scholar
[5]
Bộ Y Tế. Hướng Dẫn Chẩn Đoán và Điều Trị Ung Thư vú (Ban Hành Kèm Theo Quyết Định Số 3128/QĐ-BYT Ngày 17 Tháng 07 Năm 2020). Bộ Y Tế; 2020. Google Scholar
[6]
Phan Thị Hồng Đức. Bước đầu đánh giá hiệu quả và tính an toàn của thuốc ức chế CDK4/6 trên bệnh nhân ung thư vú di dăn HR+ HER2- tại BV Ung bướu TP Hồ Chí Minh. Tạp chí Ung thư học Việt Nam. Google Scholar
[7]
Cardoso F, W J, S K, et al. 600- vs 400-mg First-Line Ribociclib in Hormone Receptor-Positive/ERBB2-Negative Advanced Breast Cancer: The AMALEE Randomized Clinical Trial. JAMA oncology. 2025;11(11). doi:10.1001/jamaoncol.2025.3687 Google Scholar
[8]
Petrelli F, A G, R P, et al. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast cancer research and treatment. 2019;174(3). doi:10.1007/s10549-019-05133-y Google Scholar